ABSTRACT
OBJECTIVE: Knowing the risk status of malnutrition and sarcopenia in institutionalized patients is essential to understand the current context after the impact of the coronavirus (COVID-19) pandemic. METHODS: This research used a retrospective, observational study. The results of the Remote Malnutrition APP test (R-MAPP) are described: risk factors for malnutrition (including COVID-19), the Malnutrition Universal Screening Tool (MUST) and the SARC-F, in a selected sample of 402 residents of Castilla-La Mancha (Spain) during 2021. An inferential analysis was performed to determine which factors were related to the MUST (≥2 points) and SARC-F (≥4 points) response measures. With the factors that obtained statistical significance, a multivariate regression model was performed, adjusting for each one. of those factors. RESULTS: Mean age was 84.2 years, 70.1% women. Most frequent risk factor for malnutrition was aging (85.1%). The mean body mass index was 26.5 (SD 11.6). MUST≥2 points was obtained in 16.2%, and a SARC-F≥4 in 69.9%. COPD (Chronic obstructive pulmonary disease / OR 0.35; 95% CI 0.13-0.92; p 0.03) was a protective factor against the risk of malnutrition. The risk of sarcopenia was related to aging (OR 8.16; 95% CI 4.13-16.20; p 0.00), COVID-19 (OR 1.96; 95% CI 1.17-3.29; p 0.01) and COPD (OR 2.44; 95% CI 1.21-4.89; p 0.01). CONCLUSIONS: No relationship is found between COVID-19 and high risk of malnutrition. Aging, COVID-19 and COPD are risk factors for sarcopenia.
OBJETIVO: Conocer el estado de riesgo de desnutrición y sarcopenia de las personas institucionalizadas es clave para entender el contexto actual tras la repercusión que ha tenido la pandemia por coronavirus (COVID-19). METODOS: Se realizó un estudio observacional retrospectivo. Se describen los resultados de la prueba Remote Malnutrition APP (R-MAPP): factores de riesgo de desnutrición (incluyendo la COVID-19), Malnutrition Universal Screening Tool (MUST) y la SARC-F, en una muestra seleccionada de 402 residentes de Castilla-La Mancha (España) durante 2021. Se llevó a cabo un análisis inferencial para determinar qué factores tenían relación con las medidas de respuesta MUST (≥2 puntos) y SARC-F (≥4 puntos). Con los factores que obtuvieron significación estadística se realizó un modelo de regresión multivariante ajustando por cada uno de esos factores. RESULTADOS: La edad media fue de 84,2 años, con un 70,1% de mujeres. El factor de riesgo de desnutrición más frecuente fue el envejecimiento (85,1%). El Índice de Masa Corporal medio fue 26,5 (DE 11,6). Se obtuvo un MUST mayor o igual a 2 puntos en un 16,2%, y un SARC-F igual o mayor de 4 en el 69,9%. Se observó, como factor protector, la EPOC (enfermedad pulmonar obstructiva crónica / OR 0,35; IC 95% 0,13-0,92; p 0,03) contra el riesgo de desnutrición. El riesgo de sarcopenia se relacionó con envejecimiento (OR 8,16; IC 95% 4,13-16,20; p 0,00), COVID-19 (OR 1,96; IC 95% 1,17-3,29; p 0,01) y EPOC (OR 2,44; IC 95% 1,21- 4,89; p 0,01). CONCLUSIONES: No se halla relación entre COVID-19 y riesgo alto de desnutrición. Envejecimiento, COVID-19 y EPOC son factores de riesgo de sarcopenia.
Subject(s)
COVID-19 , Malnutrition , Pulmonary Disease, Chronic Obstructive , Sarcopenia , Aged , Aged, 80 and over , COVID-19/epidemiology , Female , Geriatric Assessment/methods , Humans , Male , Malnutrition/complications , Malnutrition/epidemiology , Retrospective Studies , Sarcopenia/diagnosis , Sarcopenia/epidemiology , Spain/epidemiology , Surveys and QuestionnairesABSTRACT
FUNDAMENTOS: Conocer el estado de riesgo de desnutrición y sarcopenia de las personas institucionalizadas es clave para entender el contexto actual tras la repercusión que ha tenido la pandemia por coronavirus (COVID-19). MÉTODOS: Se realizó un estudio observacional retrospectivo. Se describen los resultados de la prueba Remote Malnutrition APP (R-MAPP): factores de riesgo de desnutrición (incluyendo la COVID-19), Malnutrition Universal Screening Tool (MUST) y la SARC-F, en una muestra seleccionada de 402 residentes de Castilla-La Mancha (España) durante 2021. Se llevó a cabo un análisis inferencial para determinar qué factores tenían relación con las medidas de respuesta MUST (≥2 puntos) y SARC-F (≥4 puntos). Con los factores que obtuvieron significación estadística se realizó un modelo de regresión multivariante ajustando por cada uno de esos factores. RESULTADOS: La edad media fue de 84,2 años, con un 70,1% de mujeres. El factor de riesgo de desnutrición más frecuente fue el envejecimiento (85,1%). El Índice de Masa Corporal medio fue 26,5 (DE 11,6). Se obtuvo un MUST mayor o igual a 2 puntos en un 16,2%, y un SARC-F igual o mayor de 4 en el 69,9%. Se observó, como factor protector, la EPOC (enfermedad pulmonar obstructiva crónica / OR 0,35; IC 95% 0,13-0,92; p 0,03) contra el riesgo de desnutrición. El riesgo de sarcopenia se relacionó con envejecimiento (OR 8,16; IC 95% 4,13-16,20; p 0,00), COVID-19 (OR 1,96; IC 95% 1,17-3,29; p 0,01) y EPOC (OR 2,44; IC 95% 1,21- 4,89; p 0,01). CONCLUSIONES: No se halla relación entre COVID-19 y riesgo alto de desnutrición. Envejecimiento, COVID-19 y EPOC son factores de riesgo de sarcopenia.(AU)
BACKGROUND: Knowing the risk status of malnutrition and sarcopenia in institutionalized patients is essential to understand the current context after the impact of the coronavirus (COVID-19) pandemic. METHODS: This research used a retrospective, observational study. The results of the Remote Malnutrition APP test (R-MAPP) are described: risk factors for malnutrition (including COVID-19), the Malnutrition Universal Screening Tool (MUST) and the SARC-F, in a selected sample of 402 residents of Castilla-La Mancha (Spain) during 2021. An inferential analysis was performed to determine which factors were related to the MUST (≥2 points) and SARC-F (≥4 points) response measures. With the factors that obtained statistical significance, a multivariate regression model was performed, adjusting for each one. of those factors. RESULTS: Mean age was 84.2 years, 70.1% women. Most frequent risk factor for malnutrition was aging (85.1%). The mean body mass index was 26.5 (SD 11.6). MUST≥2 points was obtained in 16.2%, and a SARC-F≥4 in 69.9%. COPD (Chronic obstructive pulmonary disease / OR 0.35; 95% CI 0.13-0.92; p 0.03) was a protective factor against the risk of maln utrition. The risk of sarcopenia was related to aging (OR 8.16; 95% CI 4.13-16.20; p 0.00), COVID-19 (OR 1.96; 95% CI 1.17-3.29; p 0.01) and COPD (OR 2.44; 95% CI 1.21-4.89; p 0.01). CONCLUSIONS: No relationship is found between COVID-19 and high risk of malnutrition. Aging, COVID-19 and COPD are risk factors for sarcopenia.(AU)
Subject(s)
Humans , Male , Female , Aged , Malnutrition , Sarcopenia , Severe acute respiratory syndrome-related coronavirus , Betacoronavirus , Coronavirus Infections , Pandemics , Body Mass Index , Aging , Health of Institutionalized Elderly , Institutionalized Population , Spain , Public Health , Retrospective StudiesABSTRACT
INTRODUCCIÓN: El objetivo fue estimar la efectividad de la vacuna (EV) trivalente inactivada para prevenir atenciones hospitalarias por gripe (AHG) en Guadalajara, Castilla-La Mancha (CLM), España, temporada 2018-2019. MATERIAL Y MÉTODOS: Estudio de cohortes retrospectivo; semanas 40/2018 a 13/2019. Fuentes: Programa Microbiología; historia clínica electrónica; censo poblacional (INE, 1/7/2018). Casos: AHG (urgencias y/u observación de urgencias o ingreso), confirmadas mediante prueba antigénica o PCR. Se calcularon: fracciones preventivas ([FPv(vacunados) y FPp(poblacional)]) y número necesario de pacientes a vacunar (NNV). RESULTADOS: Hubo 228 AHG (tasa incidencia [TI] acumulada=8,9/104; ≥ 65 años=65%; cobertura vacunal=13% [≥ 65 años=58%]; mortalidad=9%); con máxima incidencia en la semana 6.ª (TI=1,7/104) (en CLM, en la 4.ª). El mayor pico de VRS ocurrió en la 3.ª semana (en CLM, en la 52). La FPv entre 14-65 años fue del 96% (FPp=58%) y en ≥ 65, del 32% (FPp=21%). NNV=414. Como en España, predominó el virus A, siendo A(H3N2) un 13% más prevalente (cepa no concordante con la vacunal). CONCLUSIONES: La temporada se retrasó por una sostenida circulación del VRS. La EV resultó inferior a la nacional. Sería imprescindible impulsar próximas campañas para mejorar la cobertura
INTRODUCTION: The objective was to estimate the effectiveness of inactivated trivalent vaccine (VE) in preventing hospital flu care (HFC) in Guadalajara, Castile-La Mancha (CLM), Spain, 2018-19 season. MATERIAL AND METHODS: Retrospective cohort study (40/2018 to 13/2019 weeks). Sources: Microbiology programme; electronic medical history; population census (INE, 1/7/2018). Cases: Population requiring HFC (hospital emergencies and/or emergency observation unit and/or hospital admissions), confirmed by antigenic test and/or PCR. Preventive fractions [PFv(vaccinated) and PFp(population)] and Necessary number of patients to be vaccinated (NNV) were calculated. RESULTS: 228 HFT occurred [cumulative incidence rate (IR)=8.9/104; ≥65 years=65%; vaccination coverage=13% (≥65 years=58%); mortality=9%); maximum incidence in the 6th week (IR=1.7/104) (in CLM, in 4th)]. Highest peak of RSV occurred in the 3rd (in CLM, in the 52th). PFv (14-65 years) was 96% (PFp=58%) and in ≥65, 32% (PFp=21%). NNV=414. As in Spain, influenza virus A predominated, with A(H3N2) being 13% more prevalent (strain not included in the vaccine). CONCLUSIONS: The season was delayed by sustained VRS circulation. The VE was lower than the national one. It is be essential to promote future campaigns to improve vaccination coverage
Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Child, Preschool , Child , Adolescent , Young Adult , Adult , Middle Aged , Aged , Influenza, Human/immunology , Influenza, Human/prevention & control , Treatment Outcome , Hospital Care/organization & administration , Health Services Needs and Demand , Influenza Vaccines , Cohort Studies , Vaccination Coverage , Spain , Retrospective Studies , Respiratory Syncytial Virus, Human/immunology , Respiratory Syncytial Virus Infections/epidemiologyABSTRACT
INTRODUCTION: The objective was to estimate the effectiveness of inactivated trivalent vaccine (VE) in preventing hospital flu care (HFC) in Guadalajara, Castile-La Mancha (CLM), Spain, 2018-19 season. MATERIAL AND METHODS: Retrospective cohort study (40/2018 to 13/2019 weeks). SOURCES: Microbiology programme; electronic medical history; population census (INE, 1/7/2018). CASES: Population requiring HFC (hospital emergencies and/or emergency observation unit and/or hospital admissions), confirmed by antigenic test and/or PCR. Preventive fractions [PFv(vaccinated) and PFp(population)] and Necessary number of patients to be vaccinated (NNV) were calculated. RESULTS: 228 HFT occurred [cumulative incidence rate (IR)=8.9/104; ≥65 years=65%; vaccination coverage=13% (≥65 years=58%); mortality=9%); maximum incidence in the 6th week (IR=1.7/104) (in CLM, in 4th)]. Highest peak of RSV occurred in the 3rd (in CLM, in the 52th). PFv (14-65 years) was 96% (PFp=58%) and in ≥65, 32% (PFp=21%). NNV=414. As in Spain, influenza virus A predominated, with A(H3N2) being 13% more prevalent (strain not included in the vaccine). CONCLUSIONS: The season was delayed by sustained VRS circulation. The VE was lower than the national one. It is be essential to promote future campaigns to improve vaccination coverage.